StreetInsider.com News Articles

Profound Medical Launches ‘Let's Huddle’, a Global Community Supporting Men Throughout Their Prostate Care Journey

Thu, 13 Aug 2026 16:15:00 -0400

TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, today announced the launch of Let's Huddle, a global patient community designed to empower men and their families with education, connection, and support throughout every stage of the prostate care journey.

The new patient advocacy initiative, led by Leonard Wheeler, Profound’s Global Patient Ambassador, former NFL player, prostate cancer survivor, and men's health advocate, brings together patients, survivors, care partners, healthcare professionals,

Profound Medical Launches ‘Let's Huddle’, a Global Community Supporting Men Throughout Their Prostate Care Journey

Thu, 13 Aug 2026 16:15:00 -0400

Profound Medical Launches ‘Let's Huddle’, a Global Community Supporting Men Throughout Their Prostate Care Journey

Thu, 13 Aug 2026 16:15:00 -0400

Profound Medical Launches ‘Let's Huddle’, a Global Community Supporting Men Throughout Their Prostate Care Journey

Thu, 13 Aug 2026 16:15:00 -0400

Profound Medical Launches ‘Let's Huddle’, a Global Community Supporting Men Throughout Their Prostate Care Journey

Thu, 13 Aug 2026 16:15:00 -0400

Profound Medical Launches ‘Let's Huddle’, a Global Community Supporting Men Throughout Their Prostate Care Journey

Thu, 13 Aug 2026 16:15:00 -0400

Profound Medical Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:12:00 -0400

– Operating expenses decline 16%, helping drive a 39% improvement in net loss –

– Approximately $3.1 million of TULSA revenue recognition shifts into early Q3 due to shipment timing –

– Strong clinical, commercial and reimbursement momentum continues –

– Company reiterates full-year 2026 revenue guidance –

– Announces first employer owned health plans to list the TULSA Procedure™ as a covered service –

TORONTO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage

Profound Medical Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:12:00 -0400

– Operating expenses decline 16%, helping drive a 39% improvement in net loss –

– Approximately $3.1 million of TULSA revenue recognition shifts into early Q3 due to shipment timing –

– Strong clinical, commercial and reimbursement momentum continues –

– Company reiterates full-year 2026 revenue guidance –

– Announces first employer owned health plans to list the TULSA Procedure™ as a covered service –

TORONTO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage

Profound Medical Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:12:00 -0400

– Operating expenses decline 16%, helping drive a 39% improvement in net loss –

– Approximately $3.1 million of TULSA revenue recognition shifts into early Q3 due to shipment timing –

– Strong clinical, commercial and reimbursement momentum continues –

– Company reiterates full-year 2026 revenue guidance –

– Announces first employer owned health plans to list the TULSA Procedure™ as a covered service –

TORONTO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage

Profound Medical Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:12:00 -0400

– Operating expenses decline 16%, helping drive a 39% improvement in net loss –

– Approximately $3.1 million of TULSA revenue recognition shifts into early Q3 due to shipment timing –

– Strong clinical, commercial and reimbursement momentum continues –

– Company reiterates full-year 2026 revenue guidance –

– Announces first employer owned health plans to list the TULSA Procedure™ as a covered service –

TORONTO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage

Profound Medical Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:12:00 -0400

– Operating expenses decline 16%, helping drive a 39% improvement in net loss –

– Approximately $3.1 million of TULSA revenue recognition shifts into early Q3 due to shipment timing –

– Strong clinical, commercial and reimbursement momentum continues –

– Company reiterates full-year 2026 revenue guidance –

– Announces first employer owned health plans to list the TULSA Procedure™ as a covered service –

TORONTO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage

Profound Medical Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:12:00 -0400

– Operating expenses decline 16%, helping drive a 39% improvement in net loss –

– Approximately $3.1 million of TULSA revenue recognition shifts into early Q3 due to shipment timing –

– Strong clinical, commercial and reimbursement momentum continues –

– Company reiterates full-year 2026 revenue guidance –

– Announces first employer owned health plans to list the TULSA Procedure™ as a covered service –

TORONTO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage

Telix partners with EDAP and Profound on prostate imaging tech

Fri, 15 May 2026 06:31:09 -0400

Telix Pharmaceuticals Limited (NASDAQ: TLX) announced it entered letters of intent with EDAP TMS S.A. (NASDAQ: EDAP) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN) to explore collaborations involving PSMA-PET imaging in prostate cancer treatment approaches.

The partnerships will investigate the use of Telix's PSMA-PET imaging agents Gozellix and Illuccix alongside robotic high-intensity focused ultrasound and transurethral ultrasound ablation technologies for treating localized prostate cancer. The collaborations aim to explore patient selection, treatment planning and post-treatment monitoring applications.